We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Adimab closed out 2018 with 10 new partnerships and six expanded deals. The drug discovery player is continuing that streak with three more deal expansions, with Novartis, Regeneron and Takeda.
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases,